Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins

Lancet

Volumn 368, Issue 9554, 2006, Pages 2226-2230

  Gregori, Luisa ^a   Gurgel, Patrick V ^b   Lathrop, Julia T ^c   Edwardson, Peter ^b   Lambert, Brian C ^a   Carbonell, Ruben G ^d   Burton, Steven J ^b   Hammond, David J ^c   Rohwer, Robert G ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b ProMetic Life Sciences Inc   (Canada)

^c AMERICAN RED CROSS   (United States)

^d North Carolina State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESIN;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLOOD TRANSFUSION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; ERYTHROCYTE CONCENTRATE; HAMSTER; INCUBATION TIME; INFECTION RISK; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; SCRAPIE; TITRIMETRY; WESTERN BLOTTING;

EID: 33845612714     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69897-8     Document Type: Article

References (19)

1. Houston F., Foster J., Chong A., Hunter N., and Bostock C. Transmission of BSE by blood transfusion in sheep. Lancet 356 (2000) 999-1000
2. Hunter N., Foster J., Chong A., et al. Transmission of prion diseases by blood transfusion. J General Virol 83 (2002) 2897-2905
3. Llewelyn C., Hewitt P., Knight R., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
4. Peden A., Head M., Ritchie D., Bell J., and Ironside J. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
5. Wroe S., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368 (2006) 2061-2067
6. Brown P., Cervenakova L., McShane L., Barber P., Rubenstein R., and Drohan W. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 39 (1999) 1169-1178
7. Hilton D., Ghani A., Conyers L., et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203 (2004) 733-739
8. The National Creutzfeldt-Jakob Disease Surveillance Unit, Edinburgh, Scotland. Variant Creutzfeldt-Jakob disease current data (October 2006). http://www.cjd.ed.ac.uk/vcjdworld.htm (accessed October, 2006).
9. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products, January 2002. http://www.fda.gov/cber/guidelines.htm (accessed October, 2006).
10. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang 89 (2005) 63-70
11. Minor P. Technical aspects of the development and validation of tests for variant Creutzfeldt-Jakob disease in blood transfusion. Vox Sang 86 (2004) 164-170
12. Furka A., Sebestyen F., Asgedom M., and Dibo G. General method for rapid synthesis of multicomponent peptide mixtures. Intl J Pept Protein Res 37 (1991) 487-493
13. Lam K., Salmon S., Hersh E., Hruby V., Kazmierski W., and Knapp R. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354 (1991) 82-84
14. Patent: Prion protein ligands and methods of use. Hammond D, Lathrop J, Cervenakova L, Carbonell R; WUO 2004/050851A2, filed 12/3/03.
15. Baumbach G., and Hammond D. Protein purification using affinity ligands deduced from peptide libraries. BioPharm (1992) 24-35
16. Gregori L., Lambert B., Gurgel P., et al. Reduction of TSE infectivity from human red blood cells using prion protein affinity ligands. Transfusion 46 (2006) 1152-1161
17. Gregori L., McCombie N., Palmer D., et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 364 (2004) 529-531
18. MacGregor I., Hope J., Barnard G., et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 77 (1999) 88-96
19. Brown P., Rohwer R., Dunstan B., MacAuley C., Gajdusek D., and Drohan W. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38 (1998) 810-816